AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by AEON Biopharma, Inc. on June 13, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Irvine, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected Jost Fischer and Eric Carter as Class II directors for a three-year term ending in 2028.
- Jost Fischer: 661,774 votes For; 138,295 votes Withheld; 4,357,218 Broker Non-Votes.
- Eric Carter: 674,894 votes For; 125,175 votes Withheld; 4,357,218 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2025.
- Voting Results: 4,956,438 votes For; 170,672 votes Against; 30,177 votes Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the certified voting results.
Key Facts for Investor Verification
- Confirmation that Jost Fischer and Eric Carter have officially joined the Board of Directors for the 2025-2028 term.
- Verification of KPMG LLP's status as the independent auditor for the fiscal year ending December 31, 2025.
- Review of the 2025 Proxy Statement (filed April 29, 2025) for detailed background on the director nominees and auditor selection.